In order to interrogate whether the functional connection between splicing modulation and BCL2L1 exists generally across different cancer cells/lineages, we performed drug sensitivity assays for E7107 (9 concentrations ranging from 0.15 nM–10 μM) in 478 genetically characterized human cancer cell lines covering a variety of different hematological malignancies and solid tumor types (Supplementary Data 3). Here, BCL2L1 is linked to cancer.